Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 79 articles:
HTML format



Single Articles


    September 2022
  1. LIU X, Zhang G, Yu T, He J, et al
    Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis.
    Cancer Lett. 2022;543:215781.
    PubMed     Abstract available


    July 2022
  2. RODRIGUES-FERREIRA S, Nahmias C
    Predictive biomarkers for personalized medicine in breast cancer.
    Cancer Lett. 2022;545:215828.
    PubMed     Abstract available


  3. PERDRIX ROSELL A, Maiques O, Martin JAJ, Chakravarty P, et al
    Early functional mismatch between breast cancer cells and their tumour microenvironment suppresses long term growth.
    Cancer Lett. 2022 Jul 5:215800. doi: 10.1016/j.canlet.2022.215800.
    PubMed     Abstract available


    June 2022
  4. ZHAI D, Zhang M, Li Y, Bi J, et al
    LINC01194 recruits NUMA1 to promote ubiquitination of RYR2 to enhance malignant progression in triple-negative breast cancer.
    Cancer Lett. 2022 Jun 21:215797. doi: 10.1016/j.canlet.2022.215797.
    PubMed     Abstract available


  5. MEHLICH D, Marusiak AA
    Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Cancer Lett. 2022 Jun 3:215775. doi: 10.1016/j.canlet.2022.215775.
    PubMed     Abstract available


    May 2022
  6. YUE P, Zhu Y, Brotherton-Pleiss C, Fu W, et al
    Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
    Cancer Lett. 2022;534:215613.
    PubMed     Abstract available


  7. LAW ME, Yaaghubi E, Ghilardi AF, Davis BJ, et al
    Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.
    Cancer Lett. 2022;534:215604.
    PubMed     Abstract available


  8. GOBEL A, Riffel RM, Hofbauer LC, Rachner TD, et al
    The mevalonate pathway in breast cancer biology.
    Cancer Lett. 2022 May 28:215761. doi: 10.1016/j.canlet.2022.215761.
    PubMed     Abstract available


  9. SIRKISOON SR, Wong GL, Aguayo NR, Doheny DL, et al
    Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2-->CNTF axis to promote progression of brain metastases.
    Cancer Lett. 2022 May 16:215726. doi: 10.1016/j.canlet.2022.215726.
    PubMed     Abstract available


  10. TIMILSINA S, Rajamanickam S, Rao AD, Subbarayalu P, et al
    The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
    Cancer Lett. 2022 May 11:215717. doi: 10.1016/j.canlet.2022.215717.
    PubMed     Abstract available


  11. LIU Y, Zhang Z, Gao X, Ma Q, et al
    Corrigendum to "Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B" [Canc. Lett. 535 (2022) 215629].
    Cancer Lett. 2022 May 5:215701. doi: 10.1016/j.canlet.2022.215701.
    PubMed    


    April 2022
  12. MA S, Zhang J, Guo Q, Cao C, et al
    Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics.
    Cancer Lett. 2022;530:29-44.
    PubMed     Abstract available


    March 2022
  13. YU S, Li W, Tang L, Fan X, et al
    Depression in breast cancer patients: Immunopathogenesis and immunotherapy.
    Cancer Lett. 2022;536:215648.
    PubMed     Abstract available


  14. LIU Y, Zhang Z, Gao X, Ma Q, et al
    Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B.
    Cancer Lett. 2022 Mar 9:215629. doi: 10.1016/j.canlet.2022.215629.
    PubMed     Abstract available


  15. DU G, Sun J, Li Z, Zhang Q, et al
    A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer.
    Cancer Lett. 2022 Mar 5:215618. doi: 10.1016/j.canlet.2022.215618.
    PubMed     Abstract available


  16. LYU X, Zhang Q, Fares HM, Wang Y, et al
    Contribution of adipocytes in the tumor microenvironment to breast cancer metabolism.
    Cancer Lett. 2022;534:215616.
    PubMed     Abstract available


    February 2022
  17. SCHREIBER C, Gruber A, Rosswag S, Saraswati S, et al
    Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.
    Cancer Lett. 2022 Feb 15:215600. doi: 10.1016/j.canlet.2022.215600.
    PubMed     Abstract available


    January 2022
  18. SOTO-GAMEZ A, Wang Y, Zhou X, Seras L, et al
    Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
    Cancer Lett. 2022;525:67-75.
    PubMed     Abstract available


  19. CHAIB M, Sipe LM, Yarbro JR, Bohm MS, et al
    PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8(+) T cells in breast cancer.
    Cancer Lett. 2022 Jan 21. pii: S0304-3835(22)00025.
    PubMed     Abstract available


  20. MISHRA A, Hourigan D, Lindsay AJ
    Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.
    Cancer Lett. 2022;529:153-167.
    PubMed     Abstract available


  21. PENG Y, Chen Z, He Y, Li P, et al
    Non-muscle myosin II isoforms orchestrate substrate stiffness sensing to promote cancer cell contractility and migration.
    Cancer Lett. 2022;524:245-258.
    PubMed     Abstract available


  22. ZOU Y, Liu B, Li L, Yin Q, et al
    IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors.
    Cancer Lett. 2022;524:121-130.
    PubMed     Abstract available


    December 2021
  23. WANG Z, Wang F, Ding XY, Li TE, et al
    Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.
    Cancer Lett. 2021 Dec 17. pii: S0304-3835(21)00632.
    PubMed     Abstract available


  24. CHAI C, Wu HH, Abuetabh Y, Sergi C, et al
    Regulation of the tumor suppressor PTEN in triple-negative breast cancer.
    Cancer Lett. 2021;527:41-48.
    PubMed     Abstract available


  25. TANG W, Xia M, Liao Y, Fang Y, et al
    Exosomes in triple negative breast cancer: From bench to bedside.
    Cancer Lett. 2021;527:1-9.
    PubMed     Abstract available


    November 2021
  26. CHADELLE L, Liu J, Choesmel-Cadamuro V, Karginov AV, et al
    PKCtheta-mediated serine/threonine phosphorylations of FAK govern adhesion and protrusion dynamics within the lamellipodia of migrating breast cancer cells.
    Cancer Lett. 2021 Nov 23. pii: S0304-3835(21)00599.
    PubMed     Abstract available


  27. KHUMUKCHAM SS, Penugurti V, Soni A, Uppala V, et al
    A reciprocal feedback loop between HIF-1alpha and HPIP controls phenotypic plasticity in breast cancer cells.
    Cancer Lett. 2021 Nov 9. pii: S0304-3835(21)00568.
    PubMed     Abstract available


  28. ALRAOUJI NN, Hendrayani SF, Ghebeh H, Al-Mohanna FH, et al
    Osteoprotegerin (OPG) mediates the anti-carcinogenic effects of normal breast fibroblasts and targets cancer stem cells through inhibition of the beta-catenin pathway.
    Cancer Lett. 2021;520:374-384.
    PubMed     Abstract available


  29. LEE O, Bosland MC, Wang M, Shidfar A, et al
    Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
    Cancer Lett. 2021;520:255-266.
    PubMed     Abstract available


    October 2021
  30. WANG SF, Chang YL, Tony Tzeng YD, Wu CL, et al
    Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling.
    Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00504.
    PubMed     Abstract available


  31. ALSHEIKH HAM, Metge BJ, Ha CM, Hinshaw DC, et al
    Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
    Cancer Lett. 2021;517:24-34.
    PubMed     Abstract available


    September 2021
  32. XIA M, Zu X, Chen Z, Wen G, et al
    Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance.
    Cancer Lett. 2021 Sep 30. pii: S0304-3835(21)00499.
    PubMed     Abstract available


  33. LI C, Qiu S, Jin K, Zheng X, et al
    Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression.
    Cancer Lett. 2021;523:43-56.
    PubMed     Abstract available


  34. YADAV P, Sharma P, Sundaram S, Venkatraman G, et al
    SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells.
    Cancer Lett. 2021;522:211-224.
    PubMed     Abstract available


  35. LIANG R
    Letter to the editor regarding " Marchantin A, a cyclic bis(bibenzyl ether), isolated from the liverwort Marchantia emarginata subsp. tosana induces apoptosis in human MCF-7 breast cancer cells ".
    Cancer Lett. 2021 Sep 1. pii: S0304-3835(21)00439.
    PubMed    


    August 2021
  36. WANG Y, Liang Q, Lei K, Zhu Q, et al
    Targeting MEX3A attenuates metastasis of breast cancer via beta-catenin signaling pathway inhibition.
    Cancer Lett. 2021;521:50-63.
    PubMed     Abstract available


  37. LA CAMERA G, Gelsomino L, Malivindi R, Barone I, et al
    Adipocyte-derived extracellular vesicles promote breast cancer cell malignancy through HIF-1alpha activity.
    Cancer Lett. 2021 Aug 20. pii: S0304-3835(21)00410.
    PubMed     Abstract available


  38. ZHANG M, Liu J, Liu G, Xing Z, et al
    Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies.
    Cancer Lett. 2021 Aug 10. pii: S0304-3835(21)00394.
    PubMed     Abstract available


  39. NYATI KK, Hashimoto S, Singh SK, Tekguc M, et al
    The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway.
    Cancer Lett. 2021;520:295-306.
    PubMed     Abstract available


  40. ZHU Y, Zhang H, Han X, Wang Z, et al
    STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells.
    Cancer Lett. 2021 Aug 1. pii: S0304-3835(21)00380.
    PubMed     Abstract available


    July 2021
  41. MCGARRY DJ, Armstrong G, Castino G, Mason S, et al
    MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours.
    Cancer Lett. 2021 Jul 24. pii: S0304-3835(21)00371.
    PubMed     Abstract available


  42. PENUGURTI V, Khumukcham SS, Padala C, Dwivedi A, et al
    HPIP protooncogene differentially regulates metabolic adaptation and cell fate in breast cancer cells under glucose stress via AMPK and RNF2 dependent pathways.
    Cancer Lett. 2021;518:243-255.
    PubMed     Abstract available


  43. GU J, Wang Y, Wang X, Zhou D, et al
    Retraction notice to "Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer" [Canc. Lett. 434 (2018) 1-10].
    Cancer Lett. 2021 Jul 14. pii: S0304-3835(21)00331.
    PubMed     Abstract available


  44. PETRI BJ, Piell KM, South Whitt GC, Wilt AE, et al
    HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
    Cancer Lett. 2021;518:152-168.
    PubMed     Abstract available


  45. XU X, Li N, Wang Y, Yu J, et al
    Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP.
    Cancer Lett. 2021;519:150-160.
    PubMed     Abstract available


  46. MININI M, Senni A, He X, Proietti S, et al
    miR-125a-5p impairs the metastatic potential in breast cancer via IP6K1 targeting.
    Cancer Lett. 2021 Jul 3. pii: S0304-3835(21)00326.
    PubMed     Abstract available


    June 2021
  47. HAN HJ, Sung JY, Kim SH, Yun UJ, et al
    Fibronectin regulates anoikis resistance via cell aggregate formation.
    Cancer Lett. 2021;508:59-72.
    PubMed     Abstract available


  48. SANG X, Li L, Rui C, Liu Y, et al
    Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.
    Cancer Lett. 2021;518:82-93.
    PubMed     Abstract available


  49. REGUA AT, Arrigo A, Doheny D, Wong GL, et al
    Transgenic mouse models of breast cancer.
    Cancer Lett. 2021;516:73-83.
    PubMed     Abstract available


    May 2021
  50. DIMITRAKOPOULOS FI, Kottorou A, Tzezou A
    Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer.
    Cancer Lett. 2021 May 30. pii: S0304-3835(21)00254.
    PubMed     Abstract available


  51. WANG H, Shi Y, Chen CH, Wen Y, et al
    KLF5-induced lncRNA IGFL2-AS1 promotes basal-like breast cancer cell growth and survival by upregulating the expression of IGFL1.
    Cancer Lett. 2021;515:49-62.
    PubMed     Abstract available


  52. LI X, Wang H, Yang X, Wang X, et al
    GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling.
    Cancer Lett. 2021 May 20. pii: S0304-3835(21)00194.
    PubMed     Abstract available


  53. PROVANCE OK, Geanes ES, Lui AJ, Roy A, et al
    Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression.
    Cancer Lett. 2021;514:12-29.
    PubMed     Abstract available


  54. LIGORIO F, Pellegrini I, Castagnoli L, Vingiani A, et al
    Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.
    Cancer Lett. 2021 May 4. pii: S0304-3835(21)00189.
    PubMed     Abstract available


  55. WANG M, Dai M, Wang D, Tang T, et al
    The long noncoding RNA AATBC promotes breast cancer migration and invasion by interacting with YBX1 and activating the YAP1/Hippo signaling pathway.
    Cancer Lett. 2021 May 2. pii: S0304-3835(21)00191.
    PubMed     Abstract available


    April 2021
  56. VENKATESH J, Wasson MD, Brown JM, Fernando W, et al
    LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack.
    Cancer Lett. 2021 Apr 10. pii: S0304-3835(21)00156.
    PubMed     Abstract available


  57. WANG CJ, Li D, Danielson JA, Zhang EH, et al
    Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
    Cancer Lett. 2021 Apr 1. pii: S0304-3835(21)00149.
    PubMed     Abstract available


  58. GONCALVES RM, Delgobo M, Agnes JP, das Neves RN, et al
    COX-2 promotes mammary adipose tissue inflammation, local estrogen biosynthesis, and carcinogenesis in high-sugar/fat diet treated mice.
    Cancer Lett. 2021;502:44-57.
    PubMed     Abstract available


  59. MCALEESE CE, Choudhury C, Butcher NJ, Minchin RF, et al
    Hypoxia-mediated drug resistance in breast cancers.
    Cancer Lett. 2021;502:189-199.
    PubMed     Abstract available


    March 2021
  60. KAUL K, Misri S, Ramaswamy B, Ganju RK, et al
    Contribution of the tumor and obese microenvironment to triple negative breast cancer.
    Cancer Lett. 2021 Mar 30. pii: S0304-3835(21)00141.
    PubMed     Abstract available


    February 2021
  61. SONG D, He H, Sinha I, Hases L, et al
    Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
    Cancer Lett. 2021 Feb 27. pii: S0304-3835(21)00092.
    PubMed     Abstract available


  62. HUANG M, Zhou Y, Duan D, Yang C, et al
    Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib.
    Cancer Lett. 2021 Feb 16. pii: S0304-3835(21)00074.
    PubMed     Abstract available


  63. ZHANG Y, Fan Y, Jing X, Zhao L, et al
    OTUD5-mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triple-negative breast cancer progression.
    Cancer Lett. 2021 Feb 12. pii: S0304-3835(21)00068.
    PubMed     Abstract available


  64. KUMAR S, Prajapati KS, Singh AK, Kushwaha PP, et al
    Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer.
    Cancer Lett. 2021 Feb 5. pii: S0304-3835(20)30637.
    PubMed     Abstract available


    January 2021
  65. BOURN JR, Ruiz-Torres SJ, Hunt BG, Benight NM, et al
    Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.
    Cancer Lett. 2021 Jan 25. pii: S0304-3835(21)00035.
    PubMed     Abstract available


  66. CHENG R, Wang Z, Kong X, Qi L, et al
    Factors associated with chemotherapy benefit in breast cancer patients with midrange oncotype DX breast recurrence scores.
    Cancer Lett. 2021 Jan 21. pii: S0304-3835(21)00032.
    PubMed     Abstract available


  67. LI X, Chen M, Lu W, Tang J, et al
    Targeting FAPalpha-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis.
    Cancer Lett. 2021 Jan 19. pii: S0304-3835(21)00029.
    PubMed     Abstract available


  68. YANG Y, Li S, Li B, Li Y, et al
    FBXL10 promotes ERRalpha protein stability and proliferation of breast cancer cells by enhancing the mono-ubiquitylation of ERRalpha.
    Cancer Lett. 2021 Jan 12. pii: S0304-3835(21)00023.
    PubMed     Abstract available


    December 2020
  69. SHI Y, Zhang Y, Ran F, Liu J, et al
    Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect.
    Cancer Lett. 2020;495:53-65.
    PubMed     Abstract available


  70. ZHANG T, Wu B, Akakuru OU, Yao C, et al
    Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer.
    Cancer Lett. 2020;500:41-50.
    PubMed     Abstract available


  71. MAVINGIRE N, Campbell P, Wooten J, Aja J, et al
    Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes.
    Cancer Lett. 2020 Dec 9. pii: S0304-3835(20)30664.
    PubMed     Abstract available


  72. KIM SJ, Saeidi S, Cho NC, Kim SH, et al
    Interaction of Nrf2 with dimeric STAT3 induces IL-23 expression: Implications for breast cancer progression.
    Cancer Lett. 2020 Dec 2. pii: S0304-3835(20)30645.
    PubMed     Abstract available


    November 2020
  73. WANG YY, Hung AC, Lo S, Yuan SF, et al
    Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential.
    Cancer Lett. 2020 Nov 2. pii: S0304-3835(20)30580.
    PubMed     Abstract available


  74. ZENG J, Li G, Xia Y, Wang F, et al
    miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers.
    Cancer Lett. 2020;492:185-196.
    PubMed     Abstract available


    October 2020
  75. PHAM K, Huynh D, Le L, Delitto D, et al
    E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1.
    Cancer Lett. 2020;491:132-145.
    PubMed     Abstract available


  76. BAI X, Ni J, Beretov J, Graham P, et al
    Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
    Cancer Lett. 2020;497:100-111.
    PubMed     Abstract available


  77. ZHANG N, Sun P, Xu Y, Li H, et al
    The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERalpha to inhibit the growth of breast cancer induced by oestrogen.
    Cancer Lett. 2020 Oct 15. pii: S0304-3835(20)30545.
    PubMed     Abstract available


  78. DUTTA I, Dieters-Castator D, Papatzimas JW, Medina A, et al
    ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to gammadelta T cell immunotherapy.
    Cancer Lett. 2020 Oct 9. pii: S0304-3835(20)30535.
    PubMed     Abstract available


    September 2020
  79. OH JH, Lee JY, Kim KH, Kim CY, et al
    Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.
    Cancer Lett. 2020;495:145-155.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: